share_log

BioVie | 424B3: Prospectus

BioVie | 424B3: Prospectus

BioVie | 424B3：募資說明書
美股SEC公告 ·  2024/12/03 05:23

Moomoo AI 已提取核心訊息

On December 2, 2024, BioVie announced the registration of up to 7,711,613 shares of Class A common stock for resale by selling stockholders. These shares are issuable upon the exercise of various warrants, including Private Placement I and II Warrants, and Placement Agent Warrants I-V. The company will not receive proceeds from the resale but will gain nominal cash from warrant exercises.The shares are registered to satisfy rights granted under agreements with ThinkEquity LLC, acting as placement agent. The stockholders may sell shares in different ways, with selling expenses borne by them. BioVie intends to use any proceeds from warrant exercises for working capital and corporate purposes.BioVie's common stock is traded on Nasdaq under the symbol "BIVI," with a closing price of $3.51 on November 19, 2024. Investors are advised to review risk factors before purchasing these securities.
On December 2, 2024, BioVie announced the registration of up to 7,711,613 shares of Class A common stock for resale by selling stockholders. These shares are issuable upon the exercise of various warrants, including Private Placement I and II Warrants, and Placement Agent Warrants I-V. The company will not receive proceeds from the resale but will gain nominal cash from warrant exercises.The shares are registered to satisfy rights granted under agreements with ThinkEquity LLC, acting as placement agent. The stockholders may sell shares in different ways, with selling expenses borne by them. BioVie intends to use any proceeds from warrant exercises for working capital and corporate purposes.BioVie's common stock is traded on Nasdaq under the symbol "BIVI," with a closing price of $3.51 on November 19, 2024. Investors are advised to review risk factors before purchasing these securities.
2024年12月2日，BioVie宣佈註冊最多7,711,613股A類普通股，供出售股東轉售。這些股票可在行使各種認股權證後發行，包括私募I和II認股權證以及配售代理認股權證I-V。該公司不會從轉售中獲得收益，但將從認股權證行使中獲得名義現金。這些股份的註冊是爲了滿足根據與充當配售代理人的ThinkeQuity LLC達成的協議授予的權利。股東可以用不同的方式出售股票，出售費用由他們承擔。BioVie打算將認股權證行使的任何收益用於營運資金和公司用途。BioVie的普通股在納斯達克上市，股票代碼爲 「BIVI」，2024年11月19日的收盤價爲3.51美元。建議投資者在購買這些證券之前審查風險因素。
2024年12月2日，BioVie宣佈註冊最多7,711,613股A類普通股，供出售股東轉售。這些股票可在行使各種認股權證後發行，包括私募I和II認股權證以及配售代理認股權證I-V。該公司不會從轉售中獲得收益，但將從認股權證行使中獲得名義現金。這些股份的註冊是爲了滿足根據與充當配售代理人的ThinkeQuity LLC達成的協議授予的權利。股東可以用不同的方式出售股票，出售費用由他們承擔。BioVie打算將認股權證行使的任何收益用於營運資金和公司用途。BioVie的普通股在納斯達克上市，股票代碼爲 「BIVI」，2024年11月19日的收盤價爲3.51美元。建議投資者在購買這些證券之前審查風險因素。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Aditxt
    ADTX
    -- 10.2200
    Black Diamond Therapeutics
    BDTX
    -- 2.220
    TC BioPharm
    TCBP
    -- 2.1300
    Biodexa Pharmaceuticals
    BDRX
    -- 2.3800
    CNS Pharmaceuticals
    CNSP
    -- 4.1800
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！